Latest News Archive

Please select Category, Year, and then Month to display items
Categories
UFS News Media Release Research
Years
2017 2018 2019 2020 2021 2022 2023 2024
Months
January February March April May June July August September October November December
Previous Archive
11 February 2021 Photo UFS photo archive
The National Control Laboratory for Biological Products (NCL) Building.
There can be no compromise when it comes to the quality of medicines made available to the public.

The UFS-based National Control Laboratory for Biological Products (NCL) is a full member of the international WHO-National Control Laboratory Network for Biologicals and one of 12 laboratories worldwide contracted to perform vaccine testing for the World Health Organisation (WHO). The NCL is also the only vaccine-testing laboratory in the country that performs the final quality-control testing of all human vaccine batches marketed in South Africa on behalf of the South African Health Products Regulatory Authority (SAHPRA).

In its role as a vaccine-testing laboratory for the WHO, the NCL helps to ensure that the vaccines purchased through the WHO prequalification programme for international distribution to resource-limited countries, meet the high standards of quality, safety, and efficiency. 

International testing standards

The laboratory received the status of a pharmaceutical testing laboratory after the South African Accreditation System (SANAS) endorsed its quality-management systems as of a high standard according to the International Standards Organisation’s requirements.

With its international testing standards, the NCL must ensure that all its operations – from the way documents are compiled and stored, to the maintenance of equipment and infrastructure, as well as staff competency – are performed according to international guidelines.

The laboratory has all the quality systems in place to ensure high-quality test results. The certificate of Good Manufacturing Compliance received in 2019 indicates that laboratory testing is on the expected level for any pharmaceutical testing laboratory and manufacturer. This certification is very strict and means that the NCL complies with exceptionally strict standards for pharmaceutical labs anywhere in the world. The certification offers the South African Health Products Regulatory Authority, the WHO, and other national control laboratories around the world the confidence that the test results from the NCL can be trusted.

Licensed as pharmaceutical manufacturer

The laboratory is also licensed as a pharmaceutical manufacturer. Although the lab does not manufacture, it needs to comply with manufacturing standards. It is rare for a pharmaceutical testing laboratory (such as the NCL) outside of a manufacturing context to qualify for both certifications.

News Archive

First lecture in Law Dean's series presented
2010-10-22

Prof. Johan Henning, Dean of the Faculty of Law at the UFS and Prof. Johan Farrar, a well respected Corporate Law Specialist, at the recent first lecture in the Law Dean’s Prestige Lecture Series.
Photo: Lize du Plessis
Prof. John Farrar, a well respected Corporate Law Specialist of high international repute, delivered the first lecture in the Law Dean’s Prestige Lecture Series at the University of the Free State (UFS). The theme of his paper was Directors’ duties of care – Issues of classification, solvency and business judgement and the dangers of legal transplants.

The topic is of the utmost importance to South African lawyers in view of the very contentious provisions of the new Companies Act 71 of 2008 endeavouring to introduce the business judgement rule into South African Company Law if and thus reforming company directors’ common law duties of care and skill, if when this legislation at long last becomes operative.

Prof. Farrar is a professor of Corporate Governance at the University of Auckland Business School, and joint director of the New Zealand Governance Centre. These are part-time roles and the remainder of his time is spent as emeritus professor of Law at Bond University, Queensland.

Prof. Farrar has extensive experience in Commercial Law Reform, having, for example, acted as a consultant to the New Zealand Treasury, the Law Commission, the Business Council of Australia and the UK Department of Trade and Industry.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept